Search

Abstract: A promising adsorbent for CO2 removal from flue gas was prepared by introducing tetraethylenepentamine (TEPA) into KIT-6 type mesoporous silica using post-synthetic impregnation. The as-prepared adsorbents were characterized by X-ray powder diffraction (XRD), thermal gravimetric analysis (TGA), nitrogen adsorption/desorption as well as adsorption-column-breakthrough measurements. Surface area, pore size and pore volume of TEPA-loaded KIT-6 adsorbent decrease with the increasing of TEPA loading, while its fundamental pore structure is unchanged. The dynamic adsorption capacity increases from 1.5mmol/g-adsorbent to 2.9mmol/g-adsorbent when the amount of loaded TEPA increases from 10wt.% to 50wt.% at 333K. The net adsorption capacity is about 72% of dynamic adsorption capacity. Regarding the regeneration performance of CO2 adsorbent, the suitable desorption temperature is nearly 373K. The dynamic adsorption capacity drops slightly (about 5%) during forty cycles of adsorption/desorption. The adsorbent of KIT-6 modified by TEPA exhibits excellent CO2 adsorption/desorption performance. [Copyright &y& Elsevier]

Ferroptosis is a new type of programmed cell death discovered recently and has been demonstrated to be involved in a number of human diseases such as ischemic stroke. Ferroptosis inhibitors are expected to have potential to treat these diseases. Herein, we report the identification of promethazine derivatives as a new type of ferroptosis inhibitors. Structure-activity relationship (SAR) analyses led to the discovery of the most potent compound 2-(1-(4-(4-methylpiperazin-1-yl)phenyl)ethyl)-10 H -phenothiazine (51) , which showed an EC 50 (half maximal effective concentration) value of 0.0005 μM in the erastin-induced HT1080 cell ferroptosis model. In the MCAO (middle cerebral artery occlusion) ischemic stroke model, 51 presented an excellent therapeutic effect. This compound also displayed favorable pharmacokinetic properties, in particular, a good ability to permeate the blood-brain barrier. Overall, 51 could be a promising lead compound for the treatment of ferroptosis related diseases and deserves further investigations. Image 1 • Ferroptosis is closely related to many diseases, such as stroke. • Known ferroptosis inhibitors often have poor activities and/or poor pharmacokinetic properties. • Compound 51 disclosed here excellent ferroptosis inhibitory activities both in vitro and in vivo. • Compound 51 has good pharmacokinetic properties, indicating that it is worth to warrant further study. [ABSTRACT FROM AUTHOR]